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Transmission of HIV-1 results in the establishment of a new infection, typically starting from
a single virus particle. That virion replicates to generate viremia and persistent infection in
all of the lymphoid tissue in the body. HIV-1 preferentially infects T cells with high levels
of CD4 and those subsets of T cells that express CCR5, particularly memory T cells. Most
of the replicating virus is in the lymphoid tissue, yet most of samples studied are from
blood. For the most part the tissue and blood viruses represent a well-mixed population.
With the onset of immunodeficiency, the virus evolves to infect new cell types. The
tropism switch involves switching from using CCR5 to CXCR4 and corresponds to an expan-
sion of infected cells to include naı̈ve CD4þ T cells. Similarly, the virus evolves the ability to
enter cells with low levels of CD4 on the surface and this potentiates the ability to infect
macrophages, although the scope of sites where infection of macrophages occurs and the
link to pathogenesis is only partly known and is clear only for infection of the central
nervous system. A model linking viral evolution to these two pathways has been proposed.
Finally, other disease states related to immunodeficiency may be the result of viral infection
of additional tissues, although the evidence for a direct role for the virus is less strong.
Advancing immunodeficiency creates an environment in which viral evolution results in
viral variants that can target new cell types to generate yet another class of opportunistic
infections (i.e., HIV-1 with altered tropism).
The viral population from the time of initia-tion of infection to the time of overt immu-
nodeficiency undergoes remarkable changes.
The large viral population in an infected person
is usually founded by a single infected CD4þ T
cell in the mucosal tissue proximal to the site of
exposure. For much of the time course of the
infection, viral evolution is apparent, a result
of evading the humoral and cell-mediated im-
mune responses, while the virus continues to
replicate in CD4þ T cells using CCR5 as the co-
receptor. Initially, T cells in the gut associated
lymphoid tissue (GALT) are massively depleted
even though a majority of these cells are not in
the activated state, which is preferred for HIV-1
infection in cell culture. The massive loss of
GALT CD4þ T cells happens early and therefore
cannot be the direct cause of immunodefi-
ciency, which occurs late. However, the GALT
is likely the source for a significant fraction of
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the virus in the blood, although the relationship
between production of virus in lymphoid tissue
and its transfer to the blood is unknown.
Important insights have been gained from
examining the dynamics of both the infected
cell and free virus particles, especially when
the system is perturbed with antiviral drugs.
These lessons are summarized by Coffin and
Swanstrom (2011) and they fill out the story
of virus-host interactions viewed from the per-
spective of the virus. In most settings, the virus
turns over quickly such that changes in the pro-
duction of virus are readily measured, at least
for 99.9% of the virus. Most of the time virus
is produced from CD4þ T cells that have a short
half-life. However, some cells are latently in-
fected and present a major challenge to eradica-
tion of the virus (Siliciano and Greene 2011).
Recently it has been possible to identify a var-
iant of HIV-1 that has evolved to replicate in a
new cell type with a different half-life (see
below). Thus, the dynamics of virus and in-
fected cell turnover offer important lessons into
how the virus sustains itself in the host (Coffin
and Swanstrom 2011).
Although the long-term persistent replica-
tion of virus leads to immunodeficiency, the
damage to the host that leads to this state
must be multifactorial. The early loss of most
of the CD4þ T cells in the GALT results in the
translocation of bacterial products beyond the
gut, potentially exacerbating one of the key cor-
relates of disease progression—immune activa-
tion (Lackner et al. 2011). Loss of the capacity to
make T cells and loss of the support structure to
mature and regulate T cells may also contribute
to the loss of immunologic capacity.
The onset of immunodeficiency sets the
stage for opportunistic infections by common
microbes that are otherwise controlled by the
healthy host. The virus contributes to this phe-
nomenon as shown by the appearance of var-
iants that allow the virus to replicate in new
cell types. At any one time, the virus is limited
to cell types in which it can maintain a steady-
state infection that is not cleared by the immune
system. Growth in alternative cells likely is a
challenge for the virus because replication in
suboptimal cell targets would likely result in
slow replication and easier containment by the
immune system. With immunodeficiency the
host response to replication in alternative cell
types would be slower, giving the virus a chance
to adapt to the new environment. However, in
the clearest cases the virus stays close to home
in that it always requires CD4, but can adapt
to use lower levels, and it at most swaps one che-
mokine coreceptor for another, CXCR4 for
CCR5. Whether the virus can evolve beyond
these limits in an infected host is unknown but
the tools for finding such viruses are in place.
In this article we follow the virus from trans-
mission through dissemination and the adapta-
tion to new target cells late in infection. Some of
the ideas overlap other articles, which we have
cited and which can be consulted for more
detail. The potential for the virus to generate a
localized replicating population is well estab-
lished for several tissues/compartments, and it
would not be surprising if other clear examples
are demonstrated in the future, although such
studies are difficult given the inaccessibility of
the tissues of interest. Still, the potential for
the virus to participate in pathogenic processes




Transmission is covered at length by Shaw and
Hunter (2011). There are several aspects of
transmission that influence viral pathogenesis.
In general, transmission rates for HIV-1 are
low, with the highest rates suggested to range
from 10% per exposure to 0.1% (Powers et al.
2008; Boily et al. 2009). Under these circum-
stances, it is understandable that the infecting
dose is a single virus particle; that is, limiting
rates of infection result in infection with the
minimal infectious dose. This inference has
largely been confirmed with the molecular anal-
ysis of HIV-1 present after acute infection. In
most cases, systemic infection is established by
a single genetic variant in sexual transmis-
sion, transmission by intravenous drug use, or
vertical transmission, although the frequencies
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of single variant versus multiple variant infec-
tions may vary by route (see Shaw and Hunter
2011).
Nature of the Founder Virus
There is ongoing discussion about where the
genetic bottleneck associated with transmission
occurs. There may be compartmentalization
and restriction of the population in the donor
at the site that produces the transmitted virus,
although there is little evidence in support
of this (see below). Alternatively, there may
be physical barriers that limit the exposure in
the recipient to very small amounts of virus;
such barriers might include mucus and epi-
thelium in the genital tract, which would
limit access of virus to susceptible cells. Finally,
multiple cells could become infected at the
site of transmission, but only one variant
succeed in establishing a systemic infection.
There are rare examples in which the initially
observed virus is not the same as the trans-
mitted virus (Kim et al. 2005; Russell et al.
2011). However, in the setting of low fre-
quency infection in humans, transmission of a
single variant appears to be the norm (Shaw
and Hunter 2011).
An early observation important for under-
standing viral pathogenesis was that some
viruses isolated from people late in infection
were able to grow and cause syncytia in trans-
formed T-cell lines (Asjo et al. 1986), earning
the name syncytium-inducing (SI). The re-
maining viruses were dubbed nonsyncytium-
inducing (NSI). These NSI viruses were found
early in infection and had some capacity to
infect macrophages. This supported the initial
dichotomy of less pathogenic/macrophage-
tropic viruses being transmitted (van’t Wout
et al. 1994), which evolved into more patho-
genic SI viruses. This picture has been sup-
planted with the understanding that SI viruses
use CXCR4, which is expressed on transformed
T-cell lines, in which the normal HIV-1 core-
ceptor CCR5 typically is absent, accounting
for the apparent pathogenicity in T-cell lines
of late viral isolates that have evolved to use
CXCR4 (see Wilen et al. 2011). More recently,
it was discovered that only a fraction of viruses
that use CCR5 can infect macrophages because
of the low levels of surface CD4 (see below) and
these are not the transmitted viruses. Indeed,
viruses with macrophage-tropic Env proteins
appear only late in infection, calling into ques-
tion the role of macrophage infection in sys-
temic infection. Thus the transmitted virus
typically uses CCR5 and replicates in activated
T cells as evidenced by its need for high levels
of surface CD4 (Isaacman-Beck et al. 2009;
Salazar-Gonzalez et al. 2009; Alexander et al.
2010).
Early Events in Replication
It is now clear that CD4þ T cells in or near the
epithelial layer must represent the initial target
cells for mucosal transmission. In vitro, den-
dritic cells (DCs) can efficiently capture virus
and transmit it to target CD4þ T cells in the
absence of viral replication (potentially by the
high mannose glycans on the viral Env protein
[Doores et al. 2010] binding to lectins on the
surface of DCs [Wu and KewalRamani 2006]),
but the importance of DCs facilitating the initial
infection of CD4þ T cells in vivo is still an open
question (Martin et al. 2004; Boily-Larouche
et al. 2009). In any case, there is little evidence
to suggest that viral replication in DCs is an
important part of the mechanism of trans-
mission. The initial focal replication in both
activated and resting CD4þ T cells in the prox-
imal tissue has been documented in the SIV/
macaque model (Zhang et al. 2004; Miller
et al. 2005), and this early replication is followed
by movement of the virus to proximal lymphoid
organs and then to a systemic infection (see
Lackner et al. 2011).
There are several potential mechanisms for
the virus to move from a localized infection to
a systemic infection. The simplest model is
that the concentration of virus is sufficiently
high in the extracellular space to diffuse to adja-
cent target cells and tissues. Alternatively, virus
could be transported by dendritic cells to prox-
imal lymphoid tissue. Similarly, infected T cells
could migrate to different body compartments
to deliver virus. Finally, it has been suggested
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that the viral Env protein in the transmitted
virus acts as a mimic of a4b7 integrin to target
virus to CD4þ T cells in the GALT (Nawaz et al.
2011); a corollary of this model is that viruses
without this feature might initiate a local
mucosal infection but not establish a systemic
infection because of failure to traffic to the
GALT. If stable infections were failing because
of an absence of the ability to mimic a4b7
integrin to target GALT one might expect to
see seroconversion based on transient replica-
tion in the proximal mucosal tissues, as is seen
for HSV-2 infection, but this is not observed
for putative abortive HIV-1 infections. It will
be important to place this binding property of
Env in the context of a large sampling of trans-




CD4 is required for natural isolates of HIV-1 to
infect cells. Thus, robust infection of cells is lim-
ited to those expressing CD4. The normal func-
tion of CD4 is to act as a coreceptor along with
the T-cell receptor in binding to Class II MHC,
which is on antigen presenting cells and has the
role of presenting heterologous peptides to the
CD4þ T helper cell. Other cell types can express
lower levels of CD4, for example monocytes and
macrophages, and it has been reported that CD4
plays an alternative role as the receptor for IL-16
(Liu et al. 1999).
CD4þ T cells are heterogeneous in the
expression of the CCR5 coreceptor. In the
peripheral blood the memory cell subset and
not the naive cell subset expresses significant
levels of CCR5, whereas CXCR4 is expressed at
relatively high levels on both memory and naive
CD4þ T cells (Bleul et al. 1997; Lee et al. 1999;
Nicholson et al. 2001). This pattern of CCR5
expression is consistent with memory CD4þ T
cells being the predominant cell that is infected
in vivo (Sleasman et al. 1996; Douek et al. 2002;
Brenchley et al. 2004a), with a minor popula-
tion of CD8þ T cells that express a low level of
CD4 also infected (Cochrane et al. 2004).
However, these studies have relied on linking
the presence of viral DNA to cell surface
markers, as opposed to using a marker of active
viral replication. Because of down regulation of
CD4 by HIV-1, cells actively producing virus are
seen as CD4/CD8 double-negative T cells (Kai-
ser et al. 2007). In cell culture HIV-1 infects acti-
vated cells with much greater efficiency than
quiescent cells (Korin and Zack 1998), with cen-
tral and effector memory cells as the primary
targets (Pfaff et al. 2010). However, in vivo there
appears to be a type of CD4þT cell that does not
express surface activation markers but supports
significant levels of infection, particularly in the
gut mucosa (Veazey et al. 2000; Brenchley et al.
2004b; Li et al. 2005; Mattapallil et al. 2005;
Mehandru et al. 2007).
As immunodeficiency progresses the virus
can evolve to enter cells using CXCR4 (Wilen
et al. 2011). The appearance of CXCR4-using
viruses (X4 viruses) is correlated with more
rapid progression of disease, but it is still
unclear if the evolution of these variants is the
cause or a marker of rapid disease progression
(Schuitemaker et al. 1992; Brumme et al.
2005; Hunt et al. 2006). Both may be true. X4
viruses are rarely transmitted, and it is curious
why the virus primarily uses CCR5 when
more CD4þ T cells in the blood express
CXCR4 than CCR5. However, CCR5 is gener-
ally up-regulated with infection and immune
activation and CXCR4 is down-regulated
(Ostrowski et al. 1998), and CCR5-expressing
cells are significantly enriched in lymphoid tis-
sue such as the GALT (Agace et al. 2000; Anton
et al. 2000; Veazey et al. 2003; Brenchley et al.
2004b). Naı̈ve CD4þ T cells become more
extensively infected either by infection with
the X4 virus (Blaak et al. 2000; van Rij et al.
2000) or by expansion of infection into these
cells by both the X4 and R5 viruses (Heeregrave
et al. 2009). Although R5-to-X4 evolution is
common, it is not essential for progression to
disease. A large fraction of untreated HIV-
infected individuals progress to AIDS and die
with no evidence of X4 virus.
There are distinctive sequence features of
the Env protein that allow use of CXCR4. An
accumulation of basic amino acid substitutions
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at specific positions in the V3 loop of SU is asso-
ciated with the coreceptor switch, which is pre-
sumed to increase specificity or affinity for
CXCR4 (Wilen et al. 2011). There are other
positions in Env but outside of V3 that also con-
tribute to the X4 phenotype, but the specific
contribution of these other sites is not clear
(Hoffman et al. 2002; Pastore et al. 2006; Huang
et al. 2008, 2011). There also seem to be differ-
ences among the subtypes for their propensity
to evolve X4 variants, with X4 variants being
more common in subtype D isolates (Tschern-
ing et al. 1998; Huang et al. 2007). The reason
for this difference is unclear, although the evo-
lutionary distance between R5 and X4 variants
of each subtype might be different. Conversely,
X4 variants of subtype C appear to evolve less
frequently and often include more dramatic
sequence changes in V3, including deletions,
compared to the sequence changes seen in sub-
type B (Coetzer et al. 2006, 2011).
Monocytes, Macrophages, and NK Cells
Monocytes are found in the blood and migrate
to tissue where they differentiate into macro-
phages. This can be mimicked in cell culture
by differentiating isolated blood monocytes
into macrophages (monocyte-derived macro-
phages MDM) by exposure to cytokines. Mono-
cytes and dendritic cells isolated from blood
express very low levels of CD4 (Lee et al.
1999). Peripheral monocytes have been re-
ported to be infected in vivo (Zhu et al. 2002;
Fulcher et al. 2004; Ellery et al. 2007; Xu et al.
2008), along with complex collections of other
blood myeloid cells (Centlivre et al. 2011).
However, a recent analysis of viral DNA in blood
cell subsets failed to detect a significant amount
of viral DNA in the monocyte pool (Joseffson
et al. 2011). Infection of monocytes in vitro is
limited by the low levels of surface CD4 and
blocks to entry (Arfi et al. 2008), reduced viral
DNA synthesis (Sonza et al. 1996; Triques and
Stevenson 2004; Arfi et al. 2008), and reduced
viral gene expression (Dong et al. 2009).
Macrophage-tropic viruses infect cells with
low levels of surface CD4 (Gorry et al. 2002;
Peters et al. 2004; Martin-Garcia et al. 2006;
Thomas et al. 2007). The only place where there
is clear evidence for the evolution of these
viruses is in the brain, where at least a fraction
of the cases of HIV-associated dementia involve
the presence of macrophage-tropic virus (see
Spudich and Gonzalez-Scarano 2011). There
are two potential cell targets in the brain, micro-
glia cells (macrophage-like cells in the paren-
chyma), and perivascular macrophages that
migrate into the brain as part of an inflamma-
tory response. It is not known which cell type
supports the evolution and replication of
macrophage-tropic viruses in the central nerv-
ous system (CNS). In addition to detecting
these viruses in brain tissue at autopsy, it has
now been possible to link the slow decay of
virus in the CSF during therapy (Ellis et al.
2000; Haas et al. 2000; Cinque et al. 2001;
Schnell et al. 2009), which is distinct from the
rapid decay seen in the blood (Ho et al. 1995;
Wei et al. 1995), with the presence of macro-
phage-tropic virus in the CSF, thus indicating
replication in a long-lived cell (Schnell et al.
2011).
It has been possible to isolate viruses from
blood that can enter macrophages (Li et al.
1999). However, these are not the viruses that
evolve in the CNS, which are absent from
the blood (Schnell et al. 2011) and the periph-
eral tissue (Peters et al. 2006). Understanding
the range of infection in the body by macro-
phage-tropic viruses will require sampling dif-
ferent tissues but under conditions of more
extensive disease progression to look for these
late-evolving variants. In this regard, macro-
phages appear to be preferentially infected in
macaque tissues after extensive depletion of
CD4þ T cells in lymphoid tissue by SIV (Veazey
et al. 1998; Igarashi et al. 2001).
Both X4 viruses and macrophage-tropic
viruses evolve from R5 progenitors, which
require high levels of CD4, as found on activated
T cells. Both of these variants appear late in the
disease course and are therefore linked to
increasing immunodeficiency of the host. Nei-
ther is efficiently transmitted. Thus, they both
appear to be evolutionary dead-ends that evolve
anew in each host, representing the extension
of infection into new cell types (Fig. 1). One
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evolutionary model is based on adaptation of
the Env protein structure in response to a
changing host environment (Cheng-Mayer
et al. 2009; Ince et al. 2010). This model suggests
that in the presence of a weakened antibody
response, the Env protein can evolve to be in a
more open conformation rather than the
closed, neutralization-resistant conformation
that avoids sensitivity to antibodies targeting
the coreceptor binding face. This concept is
shown in Figure 2, in which the evolution of
the open conformation may allow faster entry
into T cells but also potentiate interaction
with CXCR4 and the ability to enter cells with
lower levels of CD4, setting the stage for further
evolution.
NK cells can also be infected in vitro,
although with a limited range of viruses (Robin-
son et al. 1988; Valentin et al. 2002; Harada et al.
2007; Bernstein et al. 2009). Viral DNA can also




HIV-1 has been isolated from every bodily fluid
and it can be assumed the virus will replicate in
activated CD4þ T cells virtually anywhere in the
body. Thus, the virus is broadly disseminated in
the body. Given this wide distribution, it is not
clear what the source of virus is in the blood,
from which viral samples have been most exten-
sively studied. CD4þ T cells in the blood repre-
sent just a few percent of the CD4þ T cells in the
body, making it likely that most viral replication
is taking place in lymphoid tissues rich in CD4þ










































Figure 1. Time course of a typical HIV-1 infection with the appearance of host range variants late. The time
course for different components of the infection are shown. There is an initial loss of CD4þ T cells during acute
infection followed by a partial recovery and then a slow decay during the period of clinical latency (black line).
There is an initial viremia of the transmitted virus that uses CCR5 (R5) and requires high levels of CD4 to enter
cells, and this virus establishes a set point during the period of clinical latency (CD4Hi R5 T-cell-tropic, green
line). With the loss of CD4þT cells there is increasing immunodeficiency (AIDS, including NeuroAIDS), a trend
toward increasing viral load, and in a subset of subjects the appearance of host range variants that evolve to use a
different coreceptor (X4 T-cell-tropic, red line) or evolve the ability to infect cells, presumably macrophages,
with low levels of CD4 (CD4Low R5 M-phage-tropic, blue line).
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blood is produced by infected cells in tissue or
in blood, or if all virus-producing tissues shunt
virus into the blood with equal efficiency. Stud-
ies of tissues require biopsy or analysis of au-
topsy material, preventing careful time course
studies, and the analysis of viral sequences is
usually of DNA, which can include archival
and defective viral DNA that may not represent
the currently replicating virus. Also, free virus,
the most sensitive and reliable instantaneous
indicator of the state of infection, is not accessi-
ble from solid tissue samples. For this reason,
more accessible fluids such as semen, cervico-
vaginal mucus, and cerebral spinal fluid are often
used as surrogates for the corresponding tissue.
Genetic analysis of virus from tissues (or
their liquid surrogates) has generated several
unifying observations. In many cases the genetic
diversity of the viral population in the blood
overlaps the population in the tissue, suggesting
a well-mixed relationship in which the virus in
the blood is derived from that tissue or
imported into the tissue, and if imported into
the tissue the virus must undergo little replica-
tion given its similarity to the virus in the blood.
A variation on the mixing includes a specific
lineage of the virus in the compartment dispro-
portionately and transiently expanding, result-
ing in clonal expansion or amplification of a
subset of viral sequences. In a third scenario,
the viral population in a tissue can be distinct
from the virus in the blood, indicating an inde-
pendently replicating population that is not
exchanging between the compartments. Exam-
ples of these types of genetic relationships are
shown in Figure 3 (comparing blood and
semen, taken from Anderson et al. 2010). One
unifying model is that for many tissues virus
is imported by some mechanism from the blood
compartment at a low level, giving the appear-
ance of equilibrated populations. Only when
local viral replication reaches a level in which
it significantly increases the local viral RNA
load does it become apparent that there is an
independently replicating population that can
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Figure 2. Evolution of host range variants. In this model the variant of HIV-1 that is replicating in memory T cells
(requiring high levels of CD4 on the surface of the cell and using CCR5 as the coreceptor, shown in green) is
exposed to reduced host surveillance in the form of reduced selective pressure from antibodies. This allows
the virus to evolve such that the Env protein assumes a more open conformation that allows increased binding
to CD4. The open conformation may also expose a latent low level tropism for CXCR4. These changes potentiate
the subsequent evolution to use CXCR4 efficiently (X4 virus—red) or to use CD4 more efficiently (macrophage
tropism—blue).
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Studies of compartmentalization can be
confounded by the use of a bulk PCR strategy
to generate material for cloning and/or
sequencing. The use of cDNA end point dilu-
tion followed by multiple PCR amplifications
(also called single genome sequencing or single
genome amplification) avoids both PCR resam-
pling (which results in artifactual population
homogeneity) and PCR-mediated recombina-
tion (which confounds the genetic structure of
the population) and therefore provides the
most reliable source of sequences for the
analysis of issues dealing with viral population
structure.
Blood and Lymph Nodes
Viral populations in the blood tend to be com-
plex genetically, consistent with a large and
diverse population. The rapid decay of viral
loads with the initiation of therapy is consistent
with 99% of the virus in the blood being pro-
duced from short lived cells, presumably acti-
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88
Figure 3. Phylogenetic trees demonstrating different relationships between viral populations. In these trees are
examples of viral populations in blood (red) and semen (blue). On the left is an example of well-mixed popu-
lations with the sequences derived from blood and semen intermingled. In the middle is an example of clonal
amplification (blue bars) in which a nearly homogeneous set of sequences appears only in the semen creating a
population that is distinct from the blood. On the right is an example of compartmentalization in which the
sequences in the semen are distinct from the bulk of the sequences in the blood. These two lineages are indicated
by the circles. In addition, sequences present in the seminal tract appear to have migrated back into the blood
compartment. (These trees were originally published in Anderson et al. 2010; reprinted with permission from
the author.)
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1995). Genetic variants within this population
decay at similar rates, including both X4 and
R5 variants, indicating that the virus-producing
cells have mostly similar half-lives (Ince et al.
2009). One exception is a small percentage of
infected cells that appear to be slow to integrate
viral DNA, so that when an integrase inhibitor is
used an even larger fraction of the viral load is
accounted for in cells with a short half-life
(Murray et al. 2007). A small fraction of the
virus in the blood decays with much slower
kinetics. The significance of these populations
is discussed by Coffin and Swanstrom (2011)
and Siliciano and Greene (2011).
Within the lymph node the infected CD4þ
T cells are found outside of the germinal centers
within the paracortex (Haase 2011). In addi-
tion, there is a diffuse distribution of virus
trapped on follicular dendritic cells throughout
the lymph node (Lackner et al. 2011). The high
efficiency of virus spread between cells has the
potential to generate overlapping foci of clonal
infection, resulting in local spread of a geneti-
cally homogeneous population (Gratton et al.
2000). In this view the virus creates many inde-
pendent sites of replication in lymphoid tissue
driven by high local concentrations of virus,
with the complex population seen in the blood
the sum of production from all of these inde-
pendent foci. This effect could limit the chance
for recombination to sites of overlapping foci,
or require virus produced at distal sites to colo-
nize new tissues to allow encounter of new
recombination partners. However, the findings
of recombinants in vivo (discussed in Brown
et al. 2011), and the ease with which the entire
population turns over during development of
drug resistance, indicate there must be signifi-
cant mixing of viral populations between tissues
(Shriner et al. 2006). The similarity of the viral
sequences at blood and tissue sites implies that
they represent the same well-mixed population,
consistent with the observation that CTL escape
mutations sequentially move through these
compartments (Vanderford et al. 2011).
Ongoing viral replication eventually results
in irreversible damage in the capacity to replen-
ish CD4þ T cells. The extent of the damage is
related to the length of time of infection (or
more appropriately to the nadir of CD4þ T-
cell count). This damage is seen by an inability
to completely replace the CD4þT-cell compart-
ment after therapy in initiated (Kelley et al.
2009), which may be due in part to depletion
of the host capacity to generate CD4þ T cells
over time, or to damage of the architecture of
the lymphoid tissue that results in reduced
capacity to support CD4þ T-cell function
(Lackner et al. 2011).
Gut-Associated Lymphoid Tissue (GALT)
The GALT is the largest lymphoid tissue in the
body, containing on the order of one-half or
more of the lymphoid cells. The CD4þ T cells
in this tissue are rapidly depleted in primary
infection, more so than in the blood or other
lymphoid sites. Curiously, the cells that are
depleted are in more of a resting state rather
than an activated state, but none-the-less able
to support robust viral replication (Li et al.
1999; Veazey et al. 2000; Mehandru et al.
2007). Massive and early damage to the GALT
is proposed to contribute to damage to the
intestinal lining, which results in the transloca-
tion of bacterial products to the blood where
they have the potential to enhance the general-
ized immune activation that is a central feature
of HIV disease (see Lackner et al. 2011). Expo-
sure of an epithelial cell monolayer to virus or
purified gp120 can impair the integrity of the
monolayer through the induction of inflamma-
tory cytokines, as one potential mechanism of
damage (Nazli et al. 2010). As noted above,
there is little evidence for compartmentaliza-
tion of viral sequences between blood and
GALT, implying frequent exchange of virus or
infected cells between these sites (Vanderford
et al. 2011). Viral RNA can be detected in rectal
secretions (Zuckerman et al. 2004), however,
this virus has not been extensively studied in
terms of compartmentalization or equilibration
with the blood population of virus.
CNS
Virus can be detected in the CSF early after
infection and in many subjects throughout in-
fection (Spudich and Gonzalez-Scarano 2011).
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However, it is not clear if low levels of virus can
move (by an unknown mechanism) into the
CSF, or if detection of virus in CSF always means
there is ongoing viral replication in the CNS
itself. Compartmentalized virus, distinct from
that in blood, can be detected in the CSF (and
in brain tissue at autopsy) late in disease associ-
ated with dementia, providing clear evidence
for independent replication in the CNS. The
compartmentalized virus can involve either
macrophage-tropic or T-cell-tropic (R5) virus,
which suggests a complex interaction be-
tween HIV-1 and CNS tissue (Schnell et al.
2011). An important question in understand-
ing HIV-1 pathogenesis is determining when
independent replication can occur in the CNS
because such replication is likely to have an
associated pathogenic outcome. A compart-
mentalized CSF population has been detected
early in infection associated with a diagnosis
of aseptic meningitis, indicating the potential
for HIV-1 to establish an independently repli-
cating population of virus associated with a
pathogenic outcome even early after infection
(Schnell et al. 2010). Compartmentalization
has been detected in chronic infection in the
presence or absence of neurocognitive impair-
ment (Harrington et al. 2009). Viral replication
in the CNS will remain an important consider-
ation of viral evolution given the role of this tis-
sue in pathogenesis.
Genital Tract
There is special interest in virus in the male gen-
ital tract (MGT) and in the female genital tract
(FGT) as these are the sites involved in sexual
transmission. Virus is present in both seminal
plasma and FGT mucus in the absence of blood
contamination, indicating there must be mech-
anisms for introduction of virus into genital
secretions. A key question is whether genital
tract virus is equilibrated with the virus in the
blood or is genetically distinct, indicating local
sites of viral production.
The MGT contains potential target cells at
several anatomical sites (Le Tortorec et al.
2008). It has been reported that viral load
does not change after vasectomy, suggesting
that virus is not produced in large amounts in
the testes (Anderson et al. 1991; Krieger et al.
1998). However, this observation has not been
tied to subjects who had evidence of local pro-
duction of virus in the MGT so the lack of
involvement of the testes is clearest for virus
that is likely equilibrated with the blood. Virus
can be produced locally within the MGT
because in a subset of men the virus in semen
can be genetically distinct from the virus in
the blood (Delwart et al. 1998; Paranjpe et al.
2002; Diem et al. 2008; Anderson et al. 2010).
There appear to be two related mechanisms at
work in local production of virus. In one there
is sustained independent replication to generate
a population that is distinct from that in the
blood. In the other, there is a rapid short-term
expansion of a relatively homogeneous variant
that becomes a significant portion of the local
population. This pattern of clonal amplification
has been observed in the background of virus
that is otherwise similar to that in blood or of
virus compartmentalized within the MGT
(Anderson et al. 2010). Given the limited com-
plexity of the clonally amplified population, it
is assumed that this expansion occurs over a
short period of time but is not sustained,
although the longitudinal relationship between
clonal amplification and the long term compart-
mentalization of a genetically distinct popula-
tion is not clear.
Virus production in the FGT occurs in the
context of a thick layer of squamous epithelium
in the vagina and a single cell layer of columnar
epithelium starting at the cervix. There is no
obvious single tissue mass (equivalent to the
prostate, for example) that could provide a
source of localized virus production. Several
studies have reported compartmentalization of
viral sequences in the FMTwithin at least a sub-
set of subjects (Poss et al. 1998; Kemal et al. 2003;
Adal et al. 2005; Andreoletti et al. 2007). More
recently, this compartmentalization was inter-
preted to be largely the result of clonal amplifica-
tion (Bull et al. 2009). There is a need for both
longitudinal analysis of viral populations within
the genital tract, and an examination of the
impact of concurrent localized bacterial infec-
tions with attendant inflammation.
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Other Cell and Tissue Types
Long-term infection with HIV-1 can have a
variety of clinical manifestations in additional
organ systems. The ongoing debate is over the
extent to which they reflect infection of cells
in the affected organ, dysfunction of cells in
the organ caused by interaction with soluble
viral proteins, or indirect pathogenesis because
of concurrent systemic changes such as constit-
utive immune activation. As discussed above,
HIV-1 evolves to infect cells using a different
coreceptor (X4 tropism) and cells with low lev-
els of CD4 (macrophage tropism). Phenotypic
and genotypic evidence for viral evolution to
infect additional cell types is much less convinc-
ing compared to CXCR4 tropism and macro-
phage tropism. It is possible that alternative
cell types are fortuitously infected at a low level
in vivo, but it is not clear that infection in these
cells can be independently sustained, which
would likely be accompanied by some type of
cell-specific viral evolution. It is also possible
that such evolution goes on in one or more tis-
sue types but signatures of this process have thus
far evaded detection. Similarly, the potential
pathogenic role of soluble viral proteins is lim-
ited by the level of protein in vivo that reaches
the target cell or tissue. However, given the dif-
ficulty is sampling tissues beyond blood, much
of the work addressing these questions has been
performed in cell culture systems either by
infection or by exposure to purified viral pro-
teins; in some cases this approach has been
complemented with work using mice trans-
genic for HIV-1 genes.
Kidney: HIV-associated nephropathy can
play a significant role in end-stage renal disease
in infected people (Medapalli et al. 2011). Infec-
tion of renal epithelial cells has been frequently
invoked to explain this condition. HIV-1 sequen-
ces have been detected in these cells (Bruggeman
et al. 2000; Marras et al. 2002). The viral Nef pro-
tein has been implicated in dysregulation of cell
function through interaction with cellular signal-
ing cascades (Husain et al. 2005).
Liver: Another potential site where HIV-1
could have a pathogenic effect is the liver, in
which Kupffer cells represent at least 10% of
the total cells and are of the macrophage lineage.
It is clear that HIV-1 infection can substantially
accelerate liver disease in patients coinfected
with HIV-1 and HCV (Macias et al. 2009),
although it is not known if this is because of
general immunodeficiency or local HIV-1 repli-
cation. Viral DNA, RNA, and protein have been
detected in liver samples from HIV-1-infected
subjects (Housset et al. 1990; Cao et al. 1992;
van’t Wout et al. 1998). In cell culture systems,
HIV-1 has been reported to infect Kupffer cells
(Schmitt et al. 1990) and stellate cells (Tuyama
et al. 2010). HIV-1 infection of stellate cells
may contribute to liver fibrosis by promoting
collagen I expression and secretion of the proin-
flammatory cytokine monocyte chemoattrac-
tant protein-1 (Tuyama et al. 2010). Another
proposed pathogenic mechanism is induction
of apoptosis in hepatocytes after exposure to
HCV E2 and HIV gp120 (Munshi et al. 2003;
Vlahakis et al. 2003).
Lung: The possibility of local infection in
the lung is of interest given the importance of
the lung as the site of opportunistic infections
and pulmonary TB. Both CD4þ T cells and
alveolar macrophages are potential target cells
in the lung. The isolation of the macrophage-
tropic strain Ba-L from a lavage sample (Gart-
ner et al. 1986) is consistent with the potential
for viral replication and evolution in this com-
partment. Initial reports suggested that inde-
pendent replication can occur in the lung
(Itescu et al. 1994; Nakata et al. 1995). However,
more recent analysis of viral populations in
blood and lung showed only modest evidence
for compartmentalization (including local
clonal expansion), representing a relationship
that suggests mixing between the R5 T-cell-
tropic viruses in the blood and the lung com-
partment (Heath et al. 2009). One limitation
in the work to date in defining the genetics of
virus in the lung is that it has not focused on
later stage infections when expansion of virus
into new cell types, particularly macrophages,
is more likely to be occurring, such as during
severe immunodeficiency (Jeffrey et al. 1991).
Hematopoietic stem cells: The potential for
infection of HSC was shown many years ago
(Folks et al. 1988; Stanley et al. 1992), although
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they are relatively difficult to infect in culture
(Shen et al. 1999; Zhang et al. 2007). More
recently, interest in this phenomenon has focused
on potential pathogenic outcomes such as ane-
mia (Redd et al. 2007), oras a source of long-lived
virus making up part of the HIV-1 latent reser-
voir (Carter et al. 2010). For subtype B HIV-1
the ability to infect a multipotent cell appears
to be restricted to X4 viruses (Carter et al. 2011).
Breast: Viral dissemination into breast tissue
is relevant in the context of transmission during
breast feeding. Recent work comparing virus in
blood and breast milk has indicated that com-
partmentalization is largely limited to clonal
amplification (Gantt et al. 2010; Salazar-
Gonzalez et al. 2011). It is possible that milk
production results in a flushing effect of this
compartment that limits the opportunity for
sustained localized replication.
MECHANISM OF CELL KILLING
The mechanisms by which an infected cell dies
remain controversial. In culture, infected CD4þ
T cells die in a matter of days, whereas infected
monocyte-derived macrophages can produce
virus over a period of weeks, indicating there
is nothing inherent about viral replication that
leads to cell death. Indeed many retroviruses
infect cells without killing them. There must
be specific features of the virus and its interac-
tion with the host cell that are responsible for
cell killing. The ability to kill CD4þ T cells in
culture is consistent with the short half-life of
virus in the blood after the initiation of therapy
(Ho et al. 1995; Wei et al. 1995). That this is in
large part a virologic effect is seen by the fact
that the decay of virus in the blood goes on at
a similar rate in the presence or absence of
CD8þ cytotoxic T cells (Klatt et al. 2010). In
addition to the direct killing of infected cells, a
number of mechanisms have been proposed
that result in indirect killing of uninfected cells
because of their proximity to infected cells and
the general state of immune activation (Lackner
et al. 2011).
Many viral proteins have been implicated
as participating in cellular apoptotic (and anti-
apoptotic) pathways. Expression of Env protein
is toxic to the infected cell and surface expres-
sion can mediate syncytium formation or inter-
action with chemokine receptors on adjacent
cells. However, other viral proteins have also
been implicated in several cellular apoptotic
pathways (Varbanov et al. 2006). Recently, a
proteolytic fragment of Caspase 8, generated
by the viral protease, has been shown to induce
apoptosis through Caspase 9 activation (Sainski
et al. 2011). Also, partial viral DNA products
have been implicated in a cell killing mechanism
of abortive infection that may contribute to
apparent indirect killing (Zhou et al. 2008;
Doitsh et al. 2010). It is clear that during acute
infection massive loss of CD4þ T cells is largely
the result of direct killing of infected cells
(Li et al. 2005; Mattapallil et al. 2005). However,
the mix of direct killing versus indirect killing
over the course of the infection and the
range of mechanisms involved remain under
discussion.
SUMMARY
Viral dissemination and evolution are central to
HIV pathogenesis and the constantly changing
virus-host interaction. Evidence for evolution
to infect new cell types is strongest for X4 viruses
and macrophage-tropic viruses, but even in
these cases their contributions to viral patho-
genesis are incompletely understood. Many
additional mechanisms of viral pathogenesis
have been proposed and will continue to be
explored. The evolution of virus to form distinct
replicating populations, immune escape, or dis-
tinct entry phenotypes has provided the most
compelling evidence for the virus responding
to a changing virus-host environment. Linking
viral biology to genetic markers of viral evolu-
tion will continue to provide a strong experi-
mental paradigm for viral pathogenesis.
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